Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

1.85
+0.02001.09%
Post-market: 1.78-0.0700-3.78%18:36 EDT
Volume:47.21K
Turnover:86.14K
Market Cap:2.75M
PE:-0.01
High:1.87
Open:1.85
Low:1.79
Close:1.83
52wk High:524.00
52wk Low:1.43
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.22
T/O Rate:3.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-114.61%
ROA:-51.35%
PB:0.24
PE(LYR):-0.01

Loading ...

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder

THOMSON REUTERS
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire
·
May 12

Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data

Reuters
·
May 11

Clearmind Medicine Announces “Inside Meai” Webinar Featuring New Insights From Cmnd-100 Psychedelic Clinical Trial

THOMSON REUTERS
·
May 11

BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd

Reuters
·
May 05

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of Ptsd

THOMSON REUTERS
·
May 05

Clearmind names Hila Kiron-Revach board chair after Amitay Weiss steps down

Reuters
·
May 01

Clearmind evaluates MEAI for FDA breakthrough therapy designation in alcohol use disorder trial

Reuters
·
Apr 27

Clearmind Medicine Inc - Has Not Submitted or Received FDA Breakthrough Therapy Designation for Meai

THOMSON REUTERS
·
Apr 27

Clearmind Medicine issues $2.7 million convertible notes at 10% discount

Reuters
·
Apr 21

Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies

Reuters
·
Apr 21

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Reuters
·
Apr 20

Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial

Reuters
·
Apr 20

Clearmind Medicine Inc - Cmnd-100 Shows High Safety Profile at Highest Dosage With No Serious Adverse Events

THOMSON REUTERS
·
Apr 20

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

GlobeNewswire
·
Apr 20

Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial

TIPRANKS
·
Apr 16

Clearmind announces DSMB recommendation to continue CMND-100 trial

TIPRANKS
·
Apr 16

Clearmind advances CMND-100 alcohol use disorder trial, raises dose to 160 mg

Reuters
·
Apr 15

Clearmind Medicine Inc - Cmnd-100 Well Tolerated With No Serious Adverse Events in Third Cohort

THOMSON REUTERS
·
Apr 15

Clearmind Medicine Inc - to Proceed to Fourth Cohort, Increase Cmnd-100 Dose to 160Mg

THOMSON REUTERS
·
Apr 15